reSee.it - Related Video Feed

There are over 3,400 peer-reviewed papers in the National Library of Medicine that describe both fatal and non-fatal vaccine injury syndromes. These side effects can be categorized into four major groups: cardiovascular issues like heart inflammation and cardiac arrest, neurological problems such as stroke and neuropathy, unprecedented blood clotting that doesn't respond to typical treatments, and abnormalities in the immune system. These effects are not controversial or theoretical; they are real and have been documented extensively.

- In two worldwide embalmer blood clot surveys over the last two years, the embalmers report three key results: - Seven out of ten embalmers worldwide are seeing white fibrous clots. - The consensus is this phenomenon started in 2021, after the rollout of COVID-19 vaccines. - Embalmers are observing these white fibrous clots in an average of about 20% of their corpses (about one in every five). - Cath lab whistleblowers corroborate the presence of these clots in living patients: - Dr. Phillip McMillan (UK) has a whistleblower who has worked in the same cath lab for twenty years and reports removing between three to ten of these white fibrous clots from living patients each week in his one cath lab. - The whistleblower has access to COVID vaccination records and says 99% of the time, when he finds the white fibrous clots, the patients have received between one and eight jabs; the more jabs, the worse the clotting. - A US whistleblower, Dr. Mohammad Basharat (Jacksonville, Florida), a cardiologist and endovascular specialist, has provided email communications and photographs showing a white fibrous clot removed from a patient (a DVT) and clot images from within the body prior to removal. He has been removing these clots from living patients for the last three years. - Dr. Mendelman identified another whistleblower (Dr. Masherich) who is afraid to come out publicly due to concerns about license or board certification consequences. - Implications and specifics: - If a high percentage of the population has these clots, they could potentially grow and lead to strokes or heart attacks. - In living patients, standard anticoagulants (heparin and other clot-busting drugs) may be effective against traditional “grape jelly” clots or “chicken fat” clots but not against these white fibrous clots; thus, physical removal via catheters is often required (sucking them out or using a catheter device with a basket to scrape them out). - Symptoms and potential signs: - As the clots grow in veins and arteries, symptoms can include fatigue and chest tightness; brain fog may occur if oxygen delivery to the brain is affected. - Possible remediation and recommendations cited: - Dr. Peter McCullough has a regimen on his website involving three natural supplements—nattokinase, bromelain, and curcumin—cited as helping to break down these white fibrous clots. Nattokinase is highlighted as a natural blood thinner and is an extract of soy; the dosage, daily use, and warnings are noted on the site.

Dr. Pretorius and a colleague discuss unusual clotting observed after COVID-19 vaccination, including embalmers reporting back pressure when introducing embalming fluid and the extraction of very long, congealed clots—six inches to several feet—as well as patients with long brachial clots. They note thousands of clotting reports in VAERS across all vaccine types, describing these clots as not normal. Some clots cause major emboli affecting circulation to the lungs, detected by scans and perfusion studies, while others are microclots with a branching pattern visible in imaging. A clinician also shared a photo of a clot with a complete branching pattern into medium and smaller vessels. Dr. Pretorius’ work is cited to explain the mechanism: spike protein can induce immediate clumping of proteins in platelet-poor plasma in the absence of platelets, a highly unusual clotting pathway not relying on the classical coagulation cascade. This is described as a proteinaceous, pseudo-amyloid–like clot. The spike protein is reported to circulate after vaccination, with studies in the Journal of Immunology showing spikes in circulation and exosomes up to four months after shots. Long-haul COVID data (Patterson’s study) reportedly shows S1 protein present in nonclassical monocytes in blood, suggesting persistence of spike protein, whether from infection or the vaccine, which can induce clotting pathways on its own. Dr. Pretorius discusses observations of upregulation of intercellular adhesion molecules (ICAMs) on leukocytes within clots, causing white blood cells to adhere in addition to fibrin, contributing to difficulty in dissolving these clots. Concerning treatment and detection, the speakers describe depletion of plasminogen, reducing the body’s ability to break down clots, and note that standard anticoagulants are less effective against these clots, which are described as amyloid-like and atypical. They emphasize that these are not the classical clotting pathways involving platelet activation and typical thrombin–fibrin cascades. They contrast this with expectations of standard clotting mechanisms and reference the unusual, non-classical pathway highlighted by Pretorius. The discussion also mentions the idea that spike protein in circulation can drive clotting without the usual platelet activation, and that some patients have continued to experience spike-related effects long after vaccination. They assert that vaccines were developed targeting the original Wuhan strain and may not cover Omicron; they suggest the shot’s risk-benefit balance is unfavorable given ongoing clotting, immune suppression, and cancer-inducing pathways, and they claim data indicate those who receive two or three shots may acquire Omicron at a higher rate than those unvaccinated. They conclude that the shot is expired for a virus that is no longer circulating in its original form and argue that vaccination induces dangerous pathologic processes with no protective benefit.

The CDC in the US has found numerous issues related to vaccines. There are high rates of miscarriage, severe prematurity, and birth defects in children. The CDC comments on gynecological side effects, specifically blood clots in the placenta. Babies are being born with clots in their placenta, which may be linked to the vaccine's effects. Placenta analysis often reveals thrombosis, and healthcare professionals have reported finding small clots regularly. Further studies and analysis are needed to fully understand this issue.

Genes from injected vaccines enter bloodstream and cells lining vessel walls, producing spikes. Lymphocytes attack these cells, leading to clot formation. Antibodies appear after 3-4 weeks, attacking vessel wall cells. Vaccination creates unique situation with unknown outcome. Advises against second or any future shots due to potential dangers revealed in recent publications. Calls for discussion and action to address potential risks.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

There have been reports of blood clots in patients who have received the vaccine. These clots have been found in living patients and have also been observed in post-mortem examinations. The clots are made up of fibrous material and unusual combinations of proteins that make them difficult for the body to dissolve. However, it is important to note that not everyone who receives the vaccine will experience these clots. One possible solution is the use of an enzyme called Nattokinase, derived from fermented soy, which has been shown to break down fibrin and dissolve clots. Further research is needed to fully understand and address this issue.

There are 3,400 peer-reviewed papers in the National Library of Medicine that describe fatal and nonfatal vaccine injury syndromes. These vaccines cause real side effects in four major categories: cardiovascular issues like heart inflammation and cardiac arrest, neurologic problems such as stroke and neuropathy, unprecedented blood clotting that doesn't respond to usual treatments, and immune system abnormalities.

Speaker 0 states that the study confirms suspicions from the past five years that common sense has deteriorated in the population. The study analyzed the VAERS system from the 1990s to 2024 and examined PRRs (proportional reporting ratios), which measure how many more adverse events occur with the COVID shots compared to the flu shot or other vaccines. It reports 8686 safety signals of neuropsychiatric adverse events, with some up to 3,000 times higher than the flu shot. The safety signal threshold defined by CDC/FDA for PRRs is greater than two, and all reported signals exceeded this threshold. The listed conditions include schizophrenia, dementia, Alzheimer's, cognitive impairment, strokes, brain clots, homicidal tendencies, homicidal behavior, and psychosis, described as people hallucinating and brain damage. The speaker notes that this large number of safety signals aligns with a recent study indicating that people who had strokes showed toxic spike protein production in their brains for up to seventeen months after vaccination, which the speaker suggests explains the observed deterioration in cognitive function.

In the past, we did not see blood clotting like this before COVID-19 vaccinations. A marathon runner had severe issues walking after vaccination, requiring treatments like plasma freezes. Clot formations indicate ongoing damage to blood vessel linings, leading to clot formation. Multiple vaccinated individuals experience circulation problems in cold temperatures, with symptoms improving in warmer weather.

There are over 3,400 peer-reviewed papers in the National Library of Medicine that describe fatal and non-fatal vaccine injury syndromes. These vaccines have real side effects in four major categories: cardiovascular issues like heart inflammation and cardiac arrest, neurologic problems such as stroke and neuropathy, unprecedented blood clotting that doesn't respond to usual treatments, and immune system abnormalities.

A UK doctor and a US cardiologist have whistleblowers revealing an increase in white fibrous clots being removed from patients. Traditional clot-busting drugs are ineffective against these clots, requiring manual extraction in cath labs. The whistleblowers link the presence of these clots to COVID vaccine recipients, with 99% of patients having received 1 to 8 doses. The issue worsens with more vaccine doses. The whistleblowers fear repercussions for speaking out.

D-dimers are markers for thrombosis. When analyzing blood samples for suspected deep vein thrombosis or pulmonary embolism, the normal range should not exceed 500. However, there has been a significant increase in elevated d-dimers among vaccinated patients. Many patients have levels above 3000, leading to concerns about microthrombosis throughout the body. Despite further examinations, no embolism or thrombosis has been found. Fatigue is a common symptom among these patients. The risk is that these individuals may experience microthromboses, potentially leading to death in the future. This raises questions about the future health and insurability of those with high d-dimer levels. Investigations and studies should be conducted to understand these phenomena, including the occurrence of thrombosis in placentas during pregnancies.

The spike protein, according to research in South Africa, induces fibrin from fibrinogen, forming the backbone of clotting in a way not previously seen. Unlike normal fibrin clots that are easily broken down, clots formed from COVID or the spike protein from the vaccine are difficult to break down, causing issues for many people. A cardiologist stated that in their decades of practice, they have never treated as many blood clots as in the last five years. These blood clots occur after the virus infection and the vaccine because the spike protein causes blood clots. Therefore, it is reckless to continue vaccinating people and loading the body with spike protein, causing more blood clots. According to a paper in Cell (July 2021), the nucleoprotein, not the spike protein, supplied broad and durable immunity for the prevention of infection. The speaker questions why the vaccine wasn't changed to target the nucleoprotein once this information came to light.

There are over 3,400 peer-reviewed papers in the National Library of Medicine that describe fatal and nonfatal vaccine injury syndromes. These vaccines have been proven to cause real side effects in four major categories. Firstly, cardiovascular issues such as heart inflammation, myocarditis, and cardiac arrest. Secondly, neurologic problems including stroke, Gambray syndrome, and neuropathy. Thirdly, unprecedented blood clotting that doesn't respond to usual treatments. Lastly, immune system abnormalities. These side effects are not controversial or theoretical, but rather a reality.

I recently conducted a survey of embalmers, and 73% of the 269 respondents reported finding white fibrous clots in corpses during 2023. These clots, which consist of fibrin, platelets, and amyloid-like material, are suspected to be a contributing factor in strokes and heart attacks. Embalmers are finding these clots are making it necessary to use multiple injection sites, lengthening the embalming process. While similar clots were observed in 2020, during the initial COVID outbreak, their prevalence exploded with the introduction of vaccines in 2021. The spike protein from the virus and vaccines may be responsible for the formation of these clots. Additionally, embalmers are reporting increases in microclotting and traditional grape jelly clots. One theory suggests "frame shifting," where ribosomes misread the modified RNA code from vaccines, creating aberrant proteins that form amyloid material. I can be contacted at thomashaveland@sbcglobal.net.

The spike protein in the COVID-19 vaccines has been linked to four major domains of disease, including cardiovascular issues like heart inflammation and myocarditis. Regulatory agencies acknowledge the vaccine's association with myocarditis. As a cardiologist, I can confirm that people with myocarditis should not engage in strenuous activities as it can lead to cardiac arrest. However, sports leagues in Europe and the United States have been administering the vaccine to young individuals without medical necessity, resulting in numerous cases of cardiac arrest. Additionally, the vaccine has been proven to cause other cardiovascular diseases such as accelerated atherosclerosis and heart attacks, as well as posterior orthostatic tachycardia syndrome (POTS) leading to fainting due to low blood pressure. The vaccine is likely responsible for these issues until proven otherwise.

They said stroke only happened to the old, but hospitals started seeing something new. Healthy people suddenly clotting. Coincidence? Maybe. But after 2021, studies began tracing small patterns, inflammation, platelets, micro clots weeks after certain shots. Most never notice but for a few, the immune system hits too hard. The same spike that's meant to protect starts sticking to vessel walls. Breath thickens, flow slows, boom. Ischemia. Doctors call vaccine induced immune thrombotic events. Rare, yes, imagined, no. Its indolentacid and negem. The question isn't if it happens but why somebody's break the code. Genetics, guts, toxins, maybe all three. Because when the system builds to defend starts to misfire the result isn't protection, it's a stroke.

The entire blood supply in America and worldwide is contaminated with spike proteins from vaccines. We need to stop accepting blood from vaccinated individuals, as unvaccinated patients receiving these transfusions are experiencing serious health issues like blood clots, heart attacks, and strokes. This was predicted three years ago, and those who spoke out were silenced. It's crucial to remove the spike protein from the blood supply and hold accountable those responsible for this situation. The current management of this issue is reckless and dangerous.

Residual effects from one or two COVID shots can include late blood clots and cardiac arrests years later. The mRNA and spike protein from the shots can linger in the body, causing various health issues like heart and brain damage, blood clots, and immunologic problems. A spike detox program is recommended to address these concerns.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

Alarming data from the DMED database post-vaccine rollout in 2021 shows significant increases in various health issues. Myocarditis cases rose by 200%, while cancers increased by 300% to 900%. Infertility rates for both genders surged by 500%, and miscarriages rose by 300%. Neurological disorders saw a 1000% increase, with demyelinating disorders up by 500%, multiple sclerosis by 600%, and Guillain-Barré syndrome by 500%. Additionally, HIV cases increased by 500%, and pulmonary embolisms rose by 400%. These findings highlight serious health concerns linked to the vaccine.

There are over 3,400 peer-reviewed papers in the National Library of Medicine that describe fatal and nonfatal vaccine injury syndromes. These vaccines cause real side effects in four major categories: cardiovascular issues like heart inflammation and cardiac arrest, neurologic problems such as stroke and neuropathy, unprecedented blood clotting that doesn't respond to usual treatments, and abnormalities in the immune system.

The McCullough Foundation has conducted over 20 peer-reviewed studies exposing harms of COVID-19 shots. One study, a systematic review of autopsy findings, allegedly proved a causal link between mRNA shots and death, thus putting Brazilian kids at risk. A study by Alessandro and colleagues purportedly found a 37% life expectancy reduction in those who received two or more doses. The first largest COVID-19 vaccine safety study of 99 million people allegedly found a 500% increased risk of myocarditis and a 200-300% increased risk of spinal cord inflammation, as well as Guillain Barre syndrome. The second largest study with 85 million people reportedly found a 300% increased risk of heart attacks, strokes, arrhythmias, and coronary artery disease. Another study last week allegedly showed that people with strokes who received mRNA shots are producing spike protein in their cerebral arteries for up to 17 months.

The speaker claims injections result in blood clots, stroke, heart attack, and lost limbs, and questions why the government hasn't ordered D-dimer tests for vaccinated individuals to assess blood clot risk. Two cardiology studies allegedly found over 80% of vaccinated patients had high D-dimer levels, indicating microemboli. Microemboli in the brain, heart, or kidneys can cause organ failure and increase susceptibility to disease, potentially leading to strokes. The speaker reports seeing more cases of thrombosis of the superior sagittal sinus and transverse sinus in the brain, particularly in young people. They attribute this to microemboli and embolism caused by the spike protein from the vaccine and a nanolipid carrier entering the blood vessel wall, which they claim has been proven.